Zarzio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0076 
Minor change in labelling or package leaflet not 
05/12/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/1668/G 
This was an application for a group of variations. 
04/10/2023 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
SmPC, 
Labelling and 
PL 
WS/2530 
This was an application for a variation following a 
14/09/2023 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
WS/2506/G 
This was an application for a group of variations 
31/08/2023 
n/a 
following a worksharing procedure according to 
Page 2/26 
 
 
 
 
 
 
 
 
 
 
 
 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.f - Change in the batch size (including batch 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
WS/2484 
This was an application for a variation following a 
31/08/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.3.e - Change in batch size (including batch size 
ranges) of AS or intermediate - The scale for a 
biological/immunological AS is increased/decreased 
without process change (e.g. duplication of line) 
IB/0071/G 
This was an application for a group of variations. 
14/04/2023 
n/a 
Page 3/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
WS/2416 
This was an application for a variation following a 
09/02/2023 
09/10/2023 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
WS/2369 
This was an application for a variation following a 
12/01/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Page 4/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
WS/2380/G 
This was an application for a group of variations 
15/12/2022 
09/10/2023 
SmPC, 
Labelling and 
PL 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.e.5.b - Change in pack size of the finished 
product - Deletion of a pack size(s) 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/1548/G 
This was an application for a group of variations. 
23/08/2022 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
WS/2287/G 
This was an application for a group of variations 
14/07/2022 
09/10/2023 
SmPC, Annex 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
II, Labelling 
and PL 
Page 5/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
PSUSA/1391/
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
202109 
filgrastim 
IG/1471/G 
This was an application for a group of variations. 
07/04/2022 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
WS/2002 
This was an application for a variation following a 
10/06/2021 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
Page 6/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1311 
A.7 - Administrative change - Deletion of 
15/12/2020 
n/a 
manufacturing sites 
IG/1308/G 
This was an application for a group of variations. 
23/11/2020 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
WS/1910/G 
This was an application for a group of variations 
15/10/2020 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
WS/1925 
This was an application for a variation following a 
15/10/2020 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
WS/1873/G 
This was an application for a group of variations 
03/09/2020 
n/a 
Page 7/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.z - Quality change - Finished product - Other 
variation 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
IG/1216 
B.II.e.6.b - Change in any part of the (primary) 
04/03/2020 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0055 
B.I.a.2.a - Changes in the manufacturing process of 
21/02/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
WS/1730/G 
This was an application for a group of variations 
16/01/2020 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
Page 8/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
IG/1145 
A.4 - Administrative change - Change in the name 
18/09/2019 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
WS/1682 
This was an application for a variation following a 
12/09/2019 
17/07/2020 
PL 
Page 9/26 
 
 
 
 
 
 
 
 
 
 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
WS/1608 
This was an application for a variation following a 
11/07/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
WS/1617 
This was an application for a variation following a 
14/06/2019 
17/07/2020 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Update of sections 4.4 and 6.6 of the SmPC in order 
to remove the latex warning based on company and 
post marketing data. The Package Leaflet is updated 
accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 10/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1391/
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
201809 
filgrastim 
WS/1604 
This was an application for a variation following a 
04/04/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
WS/1551 
This was an application for a variation following a 
14/02/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IG/1034/G 
This was an application for a group of variations. 
17/12/2018 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 11/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0045/G 
This was an application for a group of variations. 
10/10/2018 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
IA/0044 
A.7 - Administrative change - Deletion of 
31/05/2018 
n/a 
manufacturing sites 
IB/0043 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/05/2018 
27/08/2018 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IAIN/0042 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
24/04/2018 
27/08/2018 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IA/0041 
B.I.b.2.a - Change in test procedure for AS or 
16/04/2018 
n/a 
starting material/reagent/intermediate - Minor 
Page 12/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes to an approved test procedure 
IB/0040 
B.I.e.5.c - Implementation of changes foreseen in an 
02/03/2018 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
WS/1275/G 
This was an application for a group of variations 
22/02/2018 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
IB/0038 
B.I.b.2.e - Change in test procedure for AS or 
31/10/2017 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
WS/0935/G 
This was an application for a group of variations 
14/09/2017 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
Page 13/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1234/2008. 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
IAIN/0037 
B.II.b.2.c.1 - Change to importer, batch release 
15/08/2017 
27/08/2018 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
WS/0954 
This was an application for a variation following a 
23/02/2017 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
N/0035 
Minor change in labelling or package leaflet not 
04/01/2017 
27/08/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0033 
B.I.b.2.e - Change in test procedure for AS or 
10/10/2016 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
Page 14/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate 
PSUSA/1391/
Periodic Safety Update EU Single assessment - 
13/05/2016 
n/a 
PRAC Recommendation - maintenance 
201509 
filgrastim 
WS/0917 
This was an application for a variation following a 
25/02/2016 
30/06/2016 
SmPC, Annex 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
WS/0779/G 
This was an application for a group of variations 
24/09/2015 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 15/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/0744/G 
This was an application for a group of variations 
02/07/2015 
30/06/2016 
SmPC and PL 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Update of the SmPC section 4.4 in order to revise the 
warning related to use of product in latex sensitive 
individuals; consequently section 6.5 has also been 
revised. 
Update of SmPC sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, 
4.8, 5.1, 5.3, and 6.4 in order to align the PI with 
the reference product Neupogen.  
The Package Leaflet is updated accordingly. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IG/0550 
B.II.b.1.a - Replacement or addition of a 
29/04/2015 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
WS/0711/G 
This was an application for a group of variations 
23/04/2015 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
Page 16/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1234/2008. 
B.I.a.3.c - Change in batch size (including batch size 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
B.I.c.1.c - Change in immediate packaging of the AS 
- Liquid ASs (non sterile) 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
IB/0024/G 
This was an application for a group of variations. 
08/10/2014 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 17/26 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
WS/0583 
This was an application for a variation following a 
26/06/2014 
06/02/2015 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0022/G 
This was an application for a group of variations. 
20/01/2014 
n/a 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0020 
B.I.a.2.a - Changes in the manufacturing process of 
07/01/2014 
n/a 
the AS - Minor change in the manufacturing process 
Page 18/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of the AS 
IA/0021 
B.III.2.b - Change to comply with Ph. Eur. or with a 
06/01/2014 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IA/0018 
A.4 - Administrative change - Change in the name 
13/12/2013 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IA/0019 
B.II.e.6.b - Change in any part of the (primary) 
11/12/2013 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/11/2013 
06/02/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0015 
Renewal of the marketing authorisation. 
19/09/2013 
13/11/2013 
SmPC, Annex 
II, Labelling 
and PL 
IB/0016 
B.I.a.3.e - Change in batch size (including batch size 
03/07/2013 
n/a 
ranges) of AS or intermediate - The scale for a 
Page 19/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
biological/immunological AS is increased/decreased 
without process change (e.g. duplication of line) 
WS/0323/G 
This was an application for a group of variations 
21/02/2013 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
to add a manufacturing and control testing site for 
Zarzio and Filgrastim Hexal drug products. As a 
consequence, changes are implemented to some 
IPCs and the batch size. 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
biological/immunological medicinal products. 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the currently approved batch size 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new tests and limits 
IB/0014 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
10/12/2012 
13/11/2013 
SmPC 
life of the finished product - As packaged for sale 
Page 20/26 
 
 
 
 
 
 
 
 
 
 
 
 
(supported by real time data) 
WS/0183 
This was an application for a variation following a 
17/11/2011 
17/11/2011 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Change in the immediate packaging of the finished 
product. 
B.II.e.1.a.3 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
N/0005 
Minor change in labelling or package leaflet not 
14/10/2011 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/0136/G 
This was an application for a group of variations 
23/06/2011 
10/08/2011 
SmPC and PL 
The MAH has submitted two type IB variations as part of a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Update of section 4.8 of the SmPC to include the 
terms Graft versus Host Disease (GvHD) and 
pseudogout as undesirable effects and update of 
section 4.4 to include a statement on traceability. 
The inclusion of GvHD was requested by the CHMP 
following the assessment of PSUR 3 and the 
additional changes were proposed by the MAH to 
bring the product information in line with the 
reference medicinal product. The Package Leaflet has 
group of variations following a worksharing procedure 
according to Article 20 of Commission Regulation (EC) No 
1234/2008, in order to align the product information of 
Zarzio and Filgrastim Hexal to the latest version available 
for the reference medicinal product Neupogen. The changes 
proposed were an update of section 4.8 of the SmPC to 
include the terms Graft versus Host Disease (GvHD) and 
pseudogout as undesirable effects and an update of section 
4.4 to include a statement on traceability. The inclusion of 
GvHD was requested by the CHMP following the 
assessment of PSUR 3 and the additional changes were 
proposed by the MAH to bring the product information in 
line with the reference medicinal product. The Package 
Page 21/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leaflet has been updated accordingly. 
been updated accordingly. 
In addition the local representatives have been 
updated in the PL.  
This was an application for a group of variations 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.3.a - Implementation of change(s) requested 
following the assessment of an USR, class labelling, a 
PSUR, RMP, FUM/SO, data submitted under A 45/46, 
or amendments to reflect a Core SPC - Changes with 
NO new additional data are submitted by the MAH 
IG/0056/G 
This was an application for a group of variations. 
23/03/2011 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.h - Changes to an existing pharmacovigilance 
Page 22/26 
 
 
 
 
 
 
 
 
 
 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used 
in the manufacture of the AS 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
WS/0059 
This was an application for a variation following a 
17/02/2011 
17/02/2011 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Additional down stream purification plant. 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
IB/0004 
B.II.f.1.d - Stability of FP - Change in storage 
17/02/2011 
n/a 
SmPC, Annex 
conditions of the finished product or the 
diluted/reconstituted product 
II, Labelling 
and PL 
WS/0023 
This was an application for a variation following a 
23/09/2010 
23/09/2010 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Page 23/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Registration of new storage location of the active 
substance 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IG/0018/G 
This was an application for a group of variations. 
09/09/2010 
n/a 
Annex II 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
N/0003 
Minor change in labelling or package leaflet not 
07/05/2010 
n/a 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IG/0001/G 
This was an application for a group of variations. 
26/03/2010 
26/03/2010 
SmPC and 
Labelling 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
Page 24/26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
II/0002 
Update of Summary of Product Characteristics 
24/09/2009 
21/10/2009 
SmPC and 
As per CHMP request following the conclusions of FUM 003, 
section 4.4 following CHMP request during FUM 003 
Labelling 
the MAH submitted an update of the SPC section 4.4 to 
assessment. The Labelling and Package Leaflet are 
bring the information in line with the one contained in the 
Page 25/26 
 
 
 
 
 
 
also updated. 
reference medicinal Product (Neupogen). 
The SPC is updated to amend recommendation of a 
Update of Summary of Product Characteristics and 
systematic record and tracking of the stem cell donors for a 
Labelling 
duration of at least 10 years. 
II/0001 
Change(s) to the manufacturing process for the 
24/09/2009 
30/09/2009 
active substance 
Change(s) to the manufacturing process for the 
active substance 
Page 26/26 
 
 
 
 
 
 
 
 
 
 
 
 
